RxDoctor Payments Data

David Hair, MD

Ophthalmology · Bakersfield, CANPI 1518173939

Payments from drug & device makers

$1,299in general payments, 2019–2025

Across 45 payments — averaging $28.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$524
  • Aerie Pharmaceuticals, Inc.$288
  • Dompe US, Inc.$228
  • AbbVie$104
  • Sun Pharmaceutical Industries Inc.$62
  • NEW World Medical,inc.$32
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$1,27999%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,299 in reported general payments places this provider in the 50th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$1,819,820
Medicare patients
3,906
Services billed
22,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj28$1,124,984
LumiganBimatoprost209$102,770
Prednisolone Acetate2,236$67,981
RestasisCyclosporine59$55,899
Cyclosporine93$35,011
Latanoprost1,632$19,367
RocklatanNetarsudil Mesylat/Latanoprost41$18,707
CombiganBrimonidine Tartrate/Timolol56$17,090
VyzultaLatanoprostene Bunod32$15,736
Ciprofloxacin Hcl1,384$14,873
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol97$14,403
RhopressaNetarsudil Mesylate32$14,023
Alphagan PBrimonidine Tartrate29$13,414
XiidraLifitegrast11$10,014
Travoprost54$9,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$228$1,124,98428 claims
AbbVieLumigan, Restasis, Combigan, Alphagan P$104$189,172353 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$288$32,73073 claims
AlconSimbrinza$524$5,61728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →